Management of Hyperkalemia in Elderly Patients

Immediate Medication Adjustments

The American College of Cardiology recommends discontinuing the ARB (olmesartan) as the primary intervention in patients with moderate hyperkalemia (K+ 5.5 mEq/L) and Stage 3b CKD (eGFR 49) 1
The European Society of Cardiology suggests continuing HCTZ as thiazide diuretics promote potassium excretion and can help lower serum potassium levels 4, 5
The American Heart Association recommends continuing nifedipine as calcium channel blockers do not affect potassium homeostasis and provide necessary blood pressure control 4

The National Kidney Foundation recommends starting sodium zirconium cyclosilicate (SZC) 10g once daily for faster correction (onset within 1 hour, mean reduction of 1.1 mEq/L over 48 hours), or patiromer 8.4g once daily if less urgent correction is acceptable (onset ~7 hours, mean reduction of 1.01 mEq/L at 4 weeks) 3, 4
The American College of Cardiology suggests avoiding sodium polystyrene sulfonate (Kayexalate) due to serious gastrointestinal adverse events, particularly in elderly patients 2, 3

The American Heart Association recommends checking serum potassium and creatinine within 3 days, then again at 7 days after discontinuing olmesartan and initiating the potassium binder 6, 1, 2
The European Society of Cardiology suggests continuing monitoring at 1, 4, 8, and 12 weeks initially, then monthly for the first 3 months 2, 3

The National Kidney Foundation recommends eliminating all potassium supplements and reviewing for other potassium-retaining medications (NSAIDs, potassium-sparing diuretics, heparin) 6
The American College of Cardiology suggests providing dietary counseling to limit high-potassium foods, though this should not be the sole intervention as it deprives patients of beneficial nutrients 3

The American Heart Association warns against combining multiple RAAS inhibitors (ACE inhibitor + ARB + aldosterone antagonist) as this dramatically increases hyperkalemia risk without additional benefit 1, 2, 3
The European Society of Cardiology advises against using thiazides as monotherapy in patients with eGFR <30 mL/min as they become ineffective, but at eGFR 49, HCTZ remains appropriate 5

The American College of Cardiology recommends considering reintroducing olmesartan at a reduced dose (10-20mg daily instead of typical 20-40mg) if blood pressure control requires it, while continuing the potassium binder, once potassium normalizes to 4.0-5.0 mEq/L with binder therapy 1, 3

The National Kidney Foundation notes that the progressive increase in hyperkalemia risk occurs when eGFR falls below 60 mL/min, and patients with eGFR 49 are in a high-risk category 4
The American Heart Association suggests that worsening renal function may require permanent discontinuation of olmesartan rather than dose reduction 7, 8